期刊
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
卷 51, 期 -, 页码 746-753出版社
ELSEVIER
DOI: 10.1016/j.jddst.2018.05.008
关键词
Co-delivery; Resveratrol; P53 gene; Synergistic effects; Cancer therapy
资金
- National High Technology Research and Development Program (863 Program) of China [2014AA020707]
- National Natural Science Foundation of China [21176046, 21503035, 21606041]
- Fundamental Research Funds for the Central Universities [DC201502020205]
In our previous study, we have carried out the synthesis of a novel peptide-cationic lipid (CDO14) for gene delivery. Herein, CDO14 liposome was used for co-delivering resveratrol and p53 gene to investigate the gene delivery efficiency of resveratrol liposomes (CDOR) and the anti-tumor effect of CDOR/p53 gene lipoplexes against cervical cancer and breast cancer cells (Hela and MCF-7 cells). The liposomes coating resveratrol were prepared using different weight ratios of CDO14/resveratrol. They were characterized by dynamic laser scattering (DLS), high performance liquid chromatography (HPLC) and agarose gel retardation assay. In vitro transfection studies revealed that the highest transfection efficiency was obtained when lipid/pDNA (N/P) weight ratio was 3/1 and Hela cells showed greater transfection efficiency than MCF-7 cells. MTT assay illustrated that co-delivery systems of reveratrol and p53 had stronger growth inhibition on Hela cells and MCF-7 cells than the blank liposomes and resveratrol liposomes, and MCF-7 cells exhibited lower cell viability than Hela cells. Hoechst 33342 assay indicated that CDOR/p53 lipoplexes were capable of inducing more cell apoptosis. We could conclude that co-delivery of resveratrol and p53 gene via CDO14 liposome may be a potential therapeutic agent for the synergistic treatment of Hela and MCF-7 cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据